Federal Register / Vol. 65, No. 114 / Tuesday, June 13, 2000 / Notices 37153

program priorities, geographic balance,

and the achievement of national

objectives.

c. The overall balance of the ICRC

program in addressing the three phases

of injury control (prevention, acute care,

and rehabilitation); the control of injury

among populations who are at increased

risk, including racial/ethnic minority

groups, the elderly and children; the

major causes of intentional and

unintentional injury; and the major

disciplines of injury control (such as

biomechanics, epidemiology, and

behavioral science).

d. Budgetary considerations. The

ACIPC will recommend annual funding

levels as detailed under the heading,

Availability of Funds.

3. Continued Funding

Continuation awards within the

project period will be made on the basis

of the availability of funds and the

following criteria:

a. The accomplishments of the current

budget period show that the applicant’s

objectives as prescribed in the yearly

work plans are being met;

b. The objectives for the new budget

period are realistic, specific, and

measurable;

c. The methods described will clearly

lead to achievement of these objectives;

d. The evaluation plan allows

management to monitor whether the

methods are effective by having clearly

defined process, impact, and outcome

objectives, and the applicant

demonstrates progress in implementing

the evaluation plan; and

e. The budget request is clearly

explained, adequately justified,

reasonable, and consistent with the

intended use of grant funds.

H. Other Requirements

Technical Reporting Requirements

Provide CDC with original plus two

copies of

1. progress report annually;

2. financial status report, no more

than 90 days after the end of the budget

period; and

3. final financial status report and

performance report, no more than 90

days after the end of the project period.

Send all reports to the Grants

Management Specialist identified in the

Where to Obtain Additional Information

section of this announcement.

The following additional

requirements are applicable to this

program. For a complete description of

each see Addendum 1 in the application

kit.

AR–1 Human Subjects Certification

AR–2 Requirements for inclusion of

Women and Racial and Ethnic

Minorities in Research

AR–3 Animal Subjects Requirements

AR–9 Paperwork Reduction Act

Requirements

AR–10 Smoke-Free Workplace

Requirement

AR–11 Healthy People 2010

AR–12 Lobbying Restrictions

AR–13 Prohibition on Use of CDC

funds for Certain Gun Control

Activities

AR–20 Conference Activities within

Grants/Cooperative Agreements

I. Authority and Catalog of Federal

Domestic Assistance Number

This program is authorized under

Sections 301, 391, 392, 393, and 394 of

the Public Health Service Act, [42

U.S.C. 241, 280b, 280b–1, 280b–1a, and

280b–2] as amended. Catalog of Federal

Domestic Assistance number is 93.136.

J. Where To Obtain Additional

Information

For this announcement and other CDC

announcements, see the CDC home page

on the Internet: http://www.cdc.gov.

To receive additional written

information and to request an

application kit, call 1–888–GRANTS4

(1–888–472–6874). You will be asked to

leave your name and address and will

be instructed to identify the

Announcement number of interest. A

complete program description and

information on application procedures

are contained in the application

package.

If you have questions after reviewing

the contents of all the documents,

business management assistance may be

obtained from: Joanne Wojcik, Grants

Management Specialist, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention (CDC), Colgate

Building, Room 3000, 2920 Brandywine

Road, Atlanta, GA 30341–4146,

Telephone 770–488–2717, Internet

address: jcw6@cdc.gov

Programmatic assistance may be

obtained from: Tom Voglesonger,

Program Manager, Office of Research

Grants, National Center for Injury

Prevention and Control, Centers for

Disease Control and Prevention (CDC),

4770 Buford Highway, NE., (K58),

Atlanta, GA 30341–3724, Telephone

770–488–4265, Internet address:

tdv1@cdc.gov.

Please refer to Announcement 01007

when requesting information and

submitting an application.

Dated: June 7, 2000.

Henry S. Cassell, III,

Acting Director, Procurement and Grants

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 00–14831 Filed 6–12–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Advisory Committee for EnergyRelated Epidemiologic Research:

Conference Call Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following conference call

meeting.

Name: Advisory Committee for

Energy-Related Epidemiologic Research

(ACERER), Subcommittee for

Management Review of the Chernobyl

Studies (SMRCS).

Time and Date: 1 p.m.–1:30 p.m.,

June 26, 2000.

Place: The conference call will

originate at the National Center for

Environmental Health (NCEH), CDC, in

Atlanta, Georgia. Please see

SUPPLEMENTARY INFORMATION for details

on accessing the conference call.

Status: Open to the public, limited

only by the availability of telephone

ports.

Purpose: This subcommittee is

charged with providing guidance to the

scientific reviewers and staff, and

reporting back to the full ACERER on

the charge from the Department and

Congress to assess the management,

goals, and objectives of the National

Cancer Institute Chernobyl studies.

Matters To Be Discussed: The

conference call agenda is to reach

consensus on the review and report

submitted by the SRMCS.

Agenda items are subject to change as

priorities dictate.

SUPPLEMENTARY INFORMATION: This

conference call is scheduled to begin at

1 p.m., Eastern Time. To participate in

the conference call, please dial 1–877–

322–9654 and enter conference code

970943. You will then be automatically

connected to the call.

CONTACT PERSON FOR MORE INFORMATION:

Michael J. Sage, Executive Secretary,

ACERER, and Acting Deputy Director,

NCEH, CDC, 4770 Buford Highway, NE,

(F–28), Atlanta, Georgia 30341–3724,

telephone 770/488–7002, fax 770/488–

7015.

37154 Federal Register / Vol. 65, No. 114 / Tuesday, June 13, 2000 / Notices

The Director, Management Analysis

and Services Office, has been delegated

the authority to sign Federal Register

notices pertaining to announcements of

meetings and other committee

management activities for both CDC and

the Agency for Toxic Substances and

Disease Registry.

Dated: June 8, 2000.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention.

[FR Doc. 00–14945 Filed 6–12–00; 8:45 am]

BILLING CODE 4163–18–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Advisory Committee on Immunization

Practices: Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following committee

meeting:

Name: Advisory Committee on

Immunization Practices (ACIP).

Times and Dates: 8:30 a.m.–6:30 p.m., June

21, 2000. 8 a.m.–4:30 p.m., June 22, 2000.

Place: Four Points Hotel by Sheraton, 1850

Cotillion Drive, Atlanta, Georgia 30338.

Status: Open to the public, limited only by

the space available.

Purpose: The Committee is charged with

advising the Director, CDC, on the

appropriate uses of immunizing agents. In

addition, under 42 U.S.C. § 1396s, the

Committee is mandated to establish and

periodically review and, as appropriate,

revise the list of vaccines for administration

to vaccine-eligible children through the

Vaccines for Children (VFC) program, along

with schedules regarding the appropriate

periodicity, dosage, and contraindications

applicable to the vaccines.

Matters To Be Discussed: The agenda will

include a discussion on the ACIP policies

and procedures; ACIP recommendations for

the pneumococcal conjugate vaccine; vaccine

additive: aluminum update; vaccine additive:

thimerosal; vaccines and autism; bioterrorism

working group; general recommendations;

anaphylaxis after MMR due to gelatin;

progress report on vaccine identification

standards initiative; status of high-speed

needle-free jet injectors for mass vaccination

campaigns; update on Geneva meeting on

rotavirus vaccination; Vaccines for Children

program update; adult working group:

pneumococcal polysaccharide update; CDC/

FDA report on two dose schedule for

hepatitis B for adolescent; update on

influenza vaccine supply; Global Alliance for

Vaccines and Immunization: progress in

supporting global immunization programs

and introduction of new vaccines; Nabi an

update from the Food and Drug

Administration; update from the National

Center for Infectious Diseases; update from

the National Immunization Program; update

from the Vaccine Injury Compensation

Program; update from the National Vaccine

Program. Other matters of relevance among

the committee’s objectives may be discussed.

Agenda items are subject to change as

priorities dictate.

Contact Person for More Information:

Gloria A. Kovach, Program Analyst,

Epidemiology and Surveillance Division,

National Immunization Program, CDC, 1600

Clifton Road, NE, m/s E61, Atlanta, Georgia

30333. Telephone 404/639–8096.

The Director, Management Analysis and

Services office has been delegated the

authority to sign Federal Register notices

pertaining to announcements of meetings and

other committee management activities for

both the Centers for Disease Control and

Prevention and the Agency for Toxic

Substances and Disease Registry.

Dated: June 8, 2000.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention.

[FR Doc. 00–14944 Filed 6–12–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 92N–0412]

Rajaram K. Matkari; Conviction

Reversal; Final Order Terminating

Debarment

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is issuing an

order, under the Federal Food, Drug,

and Cosmetic Act (the act), terminating

the debarment of Rajaram K. Matkari,

1304 Riverglen Way, Berthoud, CO

80513. FDA is issuing this order because

the U.S. District Court for the District of

Maryland issued a Writ of Error Coram

Nobis, reversing Mr. Matkari’s

conviction and Mr. Matkari applied for

termination of his debarment on this

basis.

EFFECTIVE DATE: June 13, 2000.

ADDRESSES: Submit written comments

to the Dockets Management Branch

(HFA–305), Food and Drug

Administration, 5630 Fishers Lane, rm.

1061, Rockville, MD 20852. Comments

are to be identified with the docket

number found in brackets in the

heading of this document.

FOR FURTHER INFORMATION CONTACT:

Leanne Cusumano, Center for Drug

Evaluation and Research (HFD–7), Food

and Drug Administration, 5600 Fishers

Lane, Rockville, MD 20857, 301–594–

2041.

SUPPLEMENTARY INFORMATION: In a notice

published in the Federal Register of

October 20, 1993 (58 FR 54156),

Rajaram K. Matkari was permanently

debarred from providing services in any

capacity to a person with an approved

or pending drug product application

(sections 306(c)(1)(B) and (c)(2)(A)(ii)

and 201(dd) of the act (21 U.S.C.

335a(c)(1)(B) and (c)(2)(A)(ii) and 21

U.S.C. 321(dd))). The debarment was

based on FDA’s finding that Mr. Matkari

was convicted of a felony under Federal

law for conduct relating to the

development or approval of a drug

product, or otherwise relating to the

regulation of a drug product (section

306(a)(2)(A) and (a)(2)(B) of the act). Mr.

Matkari, the former Vice President for

Regulatory Affairs and Product

Development of Pharmaceutical Basics,

Inc. (PBI), pled guilty to and was

sentenced on July 28, 1989, for giving an

unlawful gratuity, a felony offense

under 18 U.S.C. 201(c)(1)(A). The basis

for this conviction was Mr. Matkari’s

payment of approximately $2,000 to an

FDA chemistry review branch chief who

was responsible for supervising the

chemists who reviewed PBI’s

applications to determine whether those

applications met certain statutory

standards for approval.

On February 22, 2000, the U.S.

District Court for the District of

Maryland issued an order granting Mr.

Matkari’s petition for a Writ of Error

Coram Nobis in his criminal case. A

copy of the court’s order is available in

Docket No. 92N–0412. By this order, the

court reversed Mr. Matkari’s conviction.

On April 18, 2000, Mr. Matkari

petitioned for termination of debarment

under section 306(d)(3)(B)(i) of the act,

as amended by the Generic Drug

Enforcement Act. Section 306(d)(3)(B)(i)

of the act states that ‘‘If the conviction

which served as the basis for the

debarment of an individual under

subsection (a)(2) * * * is reversed, the

Secretary shall withdraw the order of

debarment.’’

Accordingly, the Senior Associate

Commissioner for Policy, Planning, and

Legislation, under section 306(d)(3)(B)(i)

of the act and under authority delegated

to him (21 CFR 5.20), is issuing this

order withdrawing the order of

permanent debarment of Rajaram K.

Matkari, thereby allowing him to

provide services in any capacity to a

person with an approved or pending

drug product application. Rajaram K.

Matkari’s debarment is terminated